Lupin recalls over 16,000 bottles of generic TB drug in US after failing tests

The affected lot has been produced at Lupin's Aurangabad plant and marketed in the US by Baltimore-based Lupin Pharma

Lupin is recalling 16,056 bottles of Rifampin capsules, used in the treatment of all forms of tuberculosis, in the US market due to a manufacturing issue, according to the United States Food and Drug Administration (USFDA).

As per the latest Enforcement Report by the US health regulator, Lupin Pharma is recalling the affected lot due to “Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.”

The affected lot has been produced at Lupin’s Aurangabad plant and marketed in the US by Baltimore-based Lupin Pharma.

Edits by EP News Bureau

 

generic TB drugLupin Pharmaproduct recallRifampin capsules
Comments (1)
Add Comment
  • soundos

    Thanks a lot for sharing this amazing blog with us. It is very helpful for me. Please keep sharing more articles like this.